Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade B 3.04 -0.98% -0.03
AGEN closed down 0.98 percent on Friday, September 13, 2019, on 64 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AGEN trend table...

Date Alert Name Type % Chg
New Uptrend Bullish -0.98%
Spinning Top Other -0.98%
Upper Bollinger Band Walk Strength -0.98%
Outside Day Range Expansion -0.98%
Overbought Stochastic Strength -0.98%
Stochastic Sell Signal Bearish -1.94%
Pocket Pivot Bullish Swing Setup -1.94%
NR7 Range Contraction -1.94%
Upper Bollinger Band Walk Strength -1.94%
Overbought Stochastic Strength -1.94%

Older signals for AGEN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Medicine Biotechnology Health Cancer Clinical Medicine Infectious Diseases Cancers Alzheimer's Disease Non Small Cell Lung Cancer Vaccination Melanoma Vaccine Metastatic Melanoma Renal Cell Carcinoma Glioma Malaria Cancer Vaccines Oncophage Agenus Experimental Cancer Treatments Genital Herpes Herpes Simplex Research Shingles
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.88
52 Week Low 1.54
Average Volume 878,793
200-Day Moving Average 2.829
50-Day Moving Average 2.6868
20-Day Moving Average 2.931
10-Day Moving Average 3.016
Average True Range 0.1284
ADX 25.62
+DI 23.4977
-DI 12.7587
Chandelier Exit (Long, 3 ATRs ) 2.8048
Chandelier Exit (Short, 3 ATRs ) 3.0152
Upper Bollinger Band 3.1623
Lower Bollinger Band 2.6997
Percent B (%b) 0.74
BandWidth 15.783009
MACD Line 0.1131
MACD Signal Line 0.1034
MACD Histogram 0.0096
Fundamentals Value
Market Cap 303.12 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -2.41
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.19
Resistance 3 (R3) 3.20 3.16 3.17
Resistance 2 (R2) 3.16 3.12 3.16 3.16
Resistance 1 (R1) 3.10 3.10 3.08 3.09 3.15
Pivot Point 3.06 3.06 3.05 3.06 3.06
Support 1 (S1) 3.00 3.02 2.98 2.99 2.93
Support 2 (S2) 2.96 3.00 2.96 2.92
Support 3 (S3) 2.90 2.96 2.92
Support 4 (S4) 2.89